INTRODUCTION
============

Autism spectrum disorders (ASDs) are devastating neurodevelopmental disorders characterized by deficits in social communication and interaction across multiple contexts as well as restricted, repetitive patterns of interests and behavior. The Centers for Disease Control recently presented that the prevalence of ASD has risen to approximately 1 in 68, and most children are not diagnosed with ASD until after 4 years of age in the United States.[@b1-cpn-15-047] Because early intensive behavioral and developmental interventions for toddlers and children with autism could improve outcomes,[@b2-cpn-15-047] there is a scientific need for reliable diagnostic ASD biomarkers that are expressed early in life. Such markers could have a significant impact on diagnosis and treatment.

Although the complex etiologies of ASD are poorly understood, the high heritability of ASD is supported by high concordance rates (from 36% to 95%) in monozygotic twins and higher recurrence risks of 11% and 19% with single-sibling involvement.[@b3-cpn-15-047]--[@b5-cpn-15-047] Rapid advances in clinical genetic testing technology have increased the diagnostic yield from about 10% a few years ago to about 30%.[@b6-cpn-15-047] However, because many of these genetic variants show incomplete penetrance and variable phenotypic expression,[@b7-cpn-15-047] the use of gene expression signature bio-markers may be informative and provide the best model for identifying ASD cases.

In particular, four studies have investigated blood-derived gene expression signatures to differentiate between ASD individuals (toddlers and children) and unaffected controls.[@b8-cpn-15-047]--[@b11-cpn-15-047] These studies focused on individuals with a mean age of 2.2 to 9.6 years who were at risk for ASD, and there were relatively high predictive accuracies (between 68% and 91%). To date, no study has demonstrated diagnostic prediction using blood-derived gene expression signatures in adult subjects with ASD. Accordingly, whether the gene expression profiles of adult individuals offer information about the ASD risk remains a critical question.

The aim of this study is to apply a transcriptomic approach to identify a gene expression signature with promising performance in the diagnostic prediction of young adults with ASD. Here, we used a published ASD microarray dataset to test the hypothesis. These methods provide researchers with the opportunity to test hypotheses without performing time-consuming, labor-intensive bench work.

METHODS
=======

Acquisition of the Microarray Data
----------------------------------

A publicly available microarray dataset (GSE26415) was downloaded from the Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) database,[@b12-cpn-15-047] which was deposited by Kuwano *et al*.[@b13-cpn-15-047] The original data included 21 samples of peripheral leukocytes obtained from young adults with ASD and age- and sex-matched controls as well as from healthy women with children with ASD and matched controls. The pre-existing clinical diagnoses of ASD were made by experienced child psychiatrist and developmental pediatrician according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR). In order to corroborate the ASD diagnosis, the Japanese version of the Autism Spectrum Quotient was completed.[@b13-cpn-15-047] The platform information was GPL6480 (Agilent-014850 Whole Human Genome Microarray 4x44K G4112F). In this study, we utilized 42 microarrays from subjects with ASD (n=21) and their matched controls (n=21) for further analyses. The demographic and clinical characteristics of the study subjects are summarized in [Table 1](#t1-cpn-15-047){ref-type="table"}.

Data Preprocessing and Selection of Differentially Expressed Genes
------------------------------------------------------------------

The raw data in .CEL format were primarily processed using R language (<http://www.r-project.org/>)[@b14-cpn-15-047] "limma" package.[@b15-cpn-15-047] The datasets were imported in R using the "read.maimages" function; the "normexp" function was used for background correction. The adjusted data were transformed with a logarithm for normalization using the quantile method ([Supplementary Fig. 1](#s1-cpn-15-047){ref-type="supplementary-material"}). Filtering was further achieved by building a criterion in which the 95th percentile of the negative probe on each array was set as a standard point of brightness. The control and low expression probes were filtered out when the probes at one-third of the total arrays were 10% less bright than the standard point. The "avereps" function was used to average the replicate spots on each array. Differentially expressed (DE) probes were identified using the moderated *t*-test from the limma package. *p* values were adjusted for multiple testing with the Bonferroni correction, and probes were called significant when the adjusted *p* value was \<0.05.

Development of a Prediction Model Using a Machine Learning Algorithm
--------------------------------------------------------------------

We applied machine learning to develop a prediction model that used DE probes extracted from the training set, differentiating between individuals with ASD and controls in the test set. Our strategy included two main types of machine learning, unsupervised and supervised learning.

For unsupervised learning, we adopted hierarchical cluster analysis using complete linkage and the Euclidean distance. Cluster analysis and visualization were performed using the "heatmap.2" function in the "gplots" package[@b16-cpn-15-047] in R.

For supervised learning, we used three different machine learning algorithms, such as the support vector machine (SVM),[@b17-cpn-15-047] K-nearest neighbors (KNN)[@b18-cpn-15-047] and linear discriminant analysis (LDA).[@b19-cpn-15-047] We performed prediction analysis in the subsequent sequential steps. Using the "set.seed" function in R, we randomly divided our data (n=42) into a training dataset (13 ASD and 13 control subjects) and test dataset (8 ASD and 8 control subjects). Each algorithm was trained on the training dataset of 26 randomly selected samples, which were labeled with DE probes. Eight ASD and 8 control subjects in the test data-set were validated. All supervised machine learning analyses were performed using the "MLinterfaces" packages[@b20-cpn-15-047] in R language.

[Supplementary Figure 2](#s2-cpn-15-047){ref-type="supplementary-material"} briefly describes the study design. The protocol of this study was reviewed and approved by the institutional review board of Hanyang University Hospital (HYUH IRB-2015-05-008).

RESULTS
=======

Altered Gene Expression Profiling between the ASD and Control Groups
--------------------------------------------------------------------

In comparing microarray data for the subjects with ASD (n=13) with those of unaffected controls (n=13) in the training dataset, a total of 19 DE probes were identified (adjusted *p* value \<0.05), including 6 up-regulated probes and 13 down-regulated probes ([Supplementary Fig. 3](#s3-cpn-15-047){ref-type="supplementary-material"}). Among the 19 probes, 15 were annotated as gene symbols using the Bioconductor "hgug4112a.db" package.[@b21-cpn-15-047] Ten of these genes (or loci) had previously reported associations with ASD ([Table 2](#t2-cpn-15-047){ref-type="table"}).

Unsupervised Machine Learning
-----------------------------

Using the 19-probe expression signature, a hierarchical cluster analysis of all samples (n=42) showed that ASDs were relatively well discriminated from controls (with the sorting of three ASD cases into the control group), suggesting that these probes could be helpful for differentiating between ASDs and controls. Detailed results from the hierarchical cluster analysis are presented in [Figure 1](#f1-cpn-15-047){ref-type="fig"}.

Supervised Machine Learning
---------------------------

For the supervised machine learning algorithms, we simply built a classifier using the 19-probe expression signature and assessed its predictive performance. With this 19-probe prediction model, the test dataset was used to validate the prediction of ASD. This validation test revealed that our prediction model successfully distinguished between the individuals with ASD and controls. Both SVM and KNN analysis accurately identified 8 individuals with ASD and 8 controls with the exception of classifying one control as ASD, resulting in a predictive accuracy of 93.8% (sensitivity of 100% and specificity of 87.5%). However, in the LDA analysis, the diagnostic prediction of ASD vs. control samples was 68.8% accurate ([Table 3](#t3-cpn-15-047){ref-type="table"}).

DISCUSSION
==========

Our analyses were designed to validate a potential biological signature using peripheral blood microarray data obtained from young Asian adults with ASD in combination with machine learning algorithms. In this exploratory study using previously published microarray data,[@b13-cpn-15-047] we identified a blood-based gene expression signature that reliably identified young adults with ASD.

These results are consistent with the findings of four previous studies that reported on gene expression signatures with high diagnostic accuracy for toddlers and children with ASD.[@b8-cpn-15-047]--[@b11-cpn-15-047] The results of this and four previous studies suggest that gene expression profiles from the peripheral blood samples contain a biological signature that could be used to predict the ASD risk in both children and young adults. According to several studies of healthy adults, the expression of most genes within individuals remains temporally stable, and only 1% to 2% of genes display significant changes over time periods of at least one month.[@b22-cpn-15-047],[@b23-cpn-15-047] In addition, previous studies observed that the cognitive, behavioral, and emotional symptoms of individuals with ASD generally persist over time.[@b24-cpn-15-047],[@b25-cpn-15-047] Therefore, the gene expression patterns underlying these long-standing phenotypes may be constant over time in the transition children to young adults.

Gene expression microarrays primarily measure messenger RNA for thousands of identified genes.[@b26-cpn-15-047] The microarrays specifically evaluate the sequence of DNA that is transcribed to RNA in the genome at a given time. Prediction models using multivariate gene expression have been widely adopted for screening, diagnosis, and prognosis.[@b27-cpn-15-047],[@b28-cpn-15-047] Several previous transcriptome-wide studies of gene expression in ASD subjects have used post mortem brain tissue[@b29-cpn-15-047]--[@b31-cpn-15-047] or peripheral blood samples.[@b8-cpn-15-047]--[@b11-cpn-15-047],[@b13-cpn-15-047] Among them, the gene expression profiles using peripheral blood have shown that RNA expression is disrupted across hundreds of genes in individuals with ASD. Blood-based analyses of gene expression profiles are encouraging because blood samples are easily obtainable from living individuals and are likely to contain ASD-relevant signatures.

Although the connection between blood and brain transcriptomic profiles is not well known, growing evidence suggests that measurements performed in tissues that are not primarily involved in the disease process may uncover disease signatures.[@b10-cpn-15-047] Sullivan *et al*.[@b32-cpn-15-047] have established a shared gene expression profile between whole blood and brain tissues suggesting that the cautious and thoughtful use of peripheral gene expression may be a useful surrogate for gene expression in the brain. Further research will be required to determine whether the dysregulated signatures in peripheral blood are actual indicators of the brain pathophysiology in ASD. Our results could also provide further evidence of the emerging consensus that peripheral blood is a potential source of biological signatures that are responsible for dysregulation of the brain and other unreachable tissues.[@b33-cpn-15-047]

The gene list in our study partially overlaps with previously reported candidate genes and loci associations for ASD ([Table 2](#t2-cpn-15-047){ref-type="table"}). These various transcriptomic changes would be representative of the genomic alteration in the ASD. Blood-derived gene expression studies of subjects with ASD repeatedly demonstrate dysregulation of immune/inflammation genes.[@b34-cpn-15-047] Regulatory factor X1 (RFX1; transcription factor regulating a wide variety of genes involved in immunity)[@b35-cpn-15-047] expression was significantly increased in the ASD group in our study. Substantial percentages of patients with ASD show peripheral markers of mitochondrial energy metabolism dysfunction.[@b36-cpn-15-047] We found the mitochondrial ribosomal protein S31 (MRPS31) expression was significantly reduced in the ASD group. In particular, we identified a probe (A_23_P399501, pyruvate kinase muscle isozyme \[PKM\]) that has the best ability for detecting whether a sample was collected from a patient with ASD ([Supplementary Fig. 4](#s4-cpn-15-047){ref-type="supplementary-material"}). The PKM expression level was significantly higher in ASD subjects than in controls. Pyruvate kinase is an enzyme involved in glycolysis. Its primary function is to catalyze the transfer of a phosphate group from phosphoenolpyruvate to adenosine diphosphate as the last step of glycolysis, generating one molecule of pyruvate and one molecule of adenosine triphosphate.[@b37-cpn-15-047] A previous study also demonstrated that the plasma pyruvate levels were higher in children with autism than in controls.[@b38-cpn-15-047] These results suggested that the PKM expression level in peripheral blood may serve as a biomarker to distinguish ASD from controls.

Our study has several limitations, mostly stemming from small sample size and lack of phenotypic information of the original data. In particular, most of ASD subjects in this study exhibited normal intelligence quotients (IQ; mean full scale IQ, 91.9), this probably does not represent the broader ASD population. Unfortunately, it is not well understood about the connection between the peripheral blood and the brain transcriptomic profiles and the influence of age factor for gene expression in subjects with ASD. The results of our study should be cautiously interpreted. If further analysis is performed on a more homogeneous dataset and validated in an independent, large cohort of cases and controls, the accuracy of the results should be higher. These strategies for class prediction analyses will help identify robust biomarkers for both the diagnosis of ASD and individualized treatment options for patients and their families.[@b39-cpn-15-047]

In conclusion, this study reveals a blood-based gene expression signature that has promising accuracy in distinguishing between young adults with ASD and age- and sex-matched unaffected controls. The ability of the 19 DE probes to correctly predict ASD samples compares favorably with the results of four previous studies on ASD diagnosis in toddlers and children. This transcriptomics approach may shed light on an important aspect of clinical biomarker discovery, offering high predictive accuracy for detecting ASD.

Supplementary Information
=========================

We thank Dr. Yuki Kuwano for generously depositing the microarray data series (GSE26415) online.

![Heat-map overview of the two-way hierarchical clustering analysis of 19 differentially-expressed probes. Each row represents the relative levels of expression for a single probe. The red or green color indicates relatively high or low expression, respectively. In the sample clustering dendrogram, red indicates autism spectrum disorder samples while blue indicates control samples.](cpn-15-047f1){#f1-cpn-15-047}

###### 

Demographic and clinical characteristics of study subjects

  Characteristic         ASD (n=21)    Control (n=21)
  ---------------------- ------------- ----------------
  Demographic                          
   Gender, male/female   17/4          17/4
   Age (yr)              26.7 (5.5)    27.0 (5.5)
  Clinical                             
   AQ                    30.2 (5.1)    NA
   WAIS                                
    VIQ                  96.2 (19.9)   NA
    PIQ                  87.5 (21.6)   NA
    FIQ                  91.9 (21.6)   NA

Values are presented as number only or mean (standard deviation).

ASD, autism spectrum disorder; AQ, autism spectrum quotient; WAIS, Wechsler Adult Intelligence Scale; IQ, intelligence quotients; VIQ, verbal IQ; PIQ, performance IQ; FIQ, full IQ; NA, not applied.

###### 

Nineteen probes significantly dysregulated[\*](#tfn4-cpn-15-047){ref-type="table-fn"} in the ASD training sample compared with the unaffected control's training sample

  Probe ID       Gene symbol   Gene name                                                     Location       logFC     *p* value   Adjusted *p* value[†](#tfn5-cpn-15-047){ref-type="table-fn"}   Evidence for association with ASD[‡](#tfn6-cpn-15-047){ref-type="table-fn"}   
  -------------- ------------- ------------------------------------------------------------- -------------- --------- ----------- -------------------------------------------------------------- ----------------------------------------------------------------------------- ----
  A_32_P9963     *HSF2*        Heat shock transcription factor 2                             6q22.31        −0.5288   3.99E-08    0.0007                                                         Deletion-duplication of 6q22.31                                               20
  A_24_P391104   *RFX1*        Regulatory factor X, 1 (influences HLA class II expression)   19p13.1        0.5379    1.16E-07    0.0021                                                         Deletion of 19p13.13-p13.11                                                   2
  A_23_P214037   *NPM1*        Nucleophosmin (nucleolar phosphoproein B23, numatrin)         5q35.1         −0.5139   4.34E-07    0.0079                                                                                                                                       
  A_32_P184330   \<NA\>                                                                                     0.5664    4.39E-07    0.0080                                                                                                                                       
  A_24_P832113   *NPM1*        Nucleophosmin (nucleolar phosphoproein B23, numatrin)         5q35.1         −0.4808   4.79E-07    0.0088                                                                                                                                       
  A_23_P119683   *MIER2*       Mesoderm induction early response 1, family member 2          19p13.3        0.3391    5.41E-07    0.0099                                                                                                                                       
  A_23_P162807   *MRPS31*      Mitochondrial ribosomal protein S31                           13q14.11       −0.4422   1.13E-06    0.0206                                                         Deletion-duplication of 13q14.11                                              15
  A_23_P88439    *TC2N*        Tandem C2 domains, nuclear                                    14q32.12       −0.4056   1.25E-06    0.0228                                                         Deletion of 14q32.11-q32.13                                                   1
  A_32_P188674   *NPM1*        Nucleophosmin (nucleolar phosphoproein B23, numatrin)         5q35.1         −0.4742   1.30E-06    0.0237                                                                                                                                       
  A_23_P399501   *PKM*         Pyruvate kinase, muscle                                       15q22          0.4023    1.32E-06    0.0242                                                                                                                                       
  A_32_P46765    *C12orf29*    Chromosome 12 open reading frame 29                           12q21.32       −0.4320   1.38E-06    0.0252                                                         Deletion of 12q21.31-q21.33                                                   1
  A_24_P927883   *JADE2*       Jade family PHD finger 2                                      5q31.1         −0.3695   1.52E-06    0.0278                                                                                                                                       
  A_23_P131676   *ACKR3*       Atypical chemokine receptor 3                                 2q37.3         −0.4413   1.66E-06    0.0303                                                         Deletion of 2q37.1-q37.3                                                      3
  A_23_P84154    *ARHGAP15*    Rho GTPase activating protein 15                              2q22.2-q22.3   −0.3958   1.69E-06    0.0309                                                         Rare single gene variant                                                      6
  A_23_P250462   *ATP6AP1*     ATPase, H+ transporting, lysosomal accessory protein 1        Xq28           0.3399    2.25E-06    0.0412                                                         Deletion-duplication of Xq27.1-q28                                            1
  A_23_P322593   *TAPT1-AS1*   TAPT1 antisense RNA 1                                         4p15.32        −0.3650   2.28E-06    0.0417                                                         Deletion of 4p16.3-p15.32                                                     2
  A_32_P173058   *TMEM41B*     Transmembrane protein 41B                                     11p15.4        −0.3388   2.40E-06    0.0438                                                         Deletion-duplication of 11p15.4                                               28
  A_23_P117424   *DCAF11*      DDB1 and CUL4 associated factor 11                            14q11.2        0.3174    2.54E-06    0.0464                                                         Duplication of 14q11.2-q21.1                                                  1
  A_32_P90685    \<NA\>                                                                                     −0.4853   2.63E-06    0.0481                                                                                                                                       

ASD, autism spectrum disorder; ID, intellectual disability; NA, not applied; logFC, log2 of fold change.

Adjusted *p* values \<0.05;

Bonferroni correction.

The Simons Foundation Autism Research Initiative (SFARI) Gene 2.0 database (available at <http://gene.sfari.org>).

###### 

Prediction performances of the 19-probe set on the test (validation) set, according to machine learning algorithms

        Accuracy (%)   Sensitivity (%)   Specificity (%)   Positive predictive value (%)   Negative predictive value (%)
  ----- -------------- ----------------- ----------------- ------------------------------- -------------------------------
  SVM   93.8           100.0             87.5              88.9                            100.0
  KNN   93.8           100.0             87.5              88.9                            100.0
  LDA   68.8           62.5              75.0              71.4                            66.7

SVM, support vector machine; KNN, K-nearest neighbor; LDA, linear discriminant analysis.
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